Literature DB >> 1982345

Striatal opiate mu-receptors are not located on dopamine nerve endings in the rat.

F Trovero1, D Herve, M Desban, J Glowinski, J P Tassin.   

Abstract

In rat striatal slices, the autoradiographic analysis of [3H]naloxone binding allows one to define highly labelled patches corresponding to the striosomes and representing about 17% of the total striatal volume, surrounded by a poorly labelled zone, the matrix. Previous studies have shown that the density of these mu-opiate receptor binding sites is decreased by about 28% following destruction of the striatal dopamine innervation suggesting a partial localization of these receptors on dopamine presynaptic nerve endings. These results were confirmed but, in addition, we have shown that a chronic (30 days) blockade of dopamine transmission obtained by treatment of the animals with a long acting neuroleptic induces a similar decrease of mu binding sites. Further experiments made with D-Pen2,D-Pen5-[tyrosyl-3-5(n)-3H] enkephalin, a selective delta opiate receptor agonist, have revealed that the density of delta opiate binding sites is decreased (30%) in rats with striatal dopamine denervation but not in those treated with the long acting neuroleptic. These data indicate that part of these delta receptors is located on dopamine nerve terminals but are not in favour of the presence of mu receptors on these nerve terminals. The decrease in [3H]naloxone binding sites induced by prolonged interruption of dopamine transmission can be attributed to postsynaptic events.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1982345     DOI: 10.1016/0306-4522(90)90270-e

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  14 in total

1.  Characterization of the decrease of extracellular striatal dopamine induced by intrastriatal morphine administration.

Authors:  T P Piepponen; J A Mikkola; M Ruotsalainen; D Jonker; L Ahtee
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Distinct presynaptic control of dopamine release in striosomal- and matrix-enriched areas of the rat striatum by selective agonists of NK1, NK2, and NK3 tachykinin receptors.

Authors:  L Tremblay; M L Kemel; M Desban; C Gauchy; J Glowinski
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

3.  Opioid receptors in midbrain dopaminergic regions of the rat. I. Mu receptor autoradiography.

Authors:  D C German; S G Speciale; K F Manaye; M Sadeq
Journal:  J Neural Transm Gen Sect       Date:  1993

4.  Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors.

Authors:  Hui Zhang; David Sulzer
Journal:  Basal Ganglia       Date:  2012-03-01

Review 5.  How addictive drugs disrupt presynaptic dopamine neurotransmission.

Authors:  David Sulzer
Journal:  Neuron       Date:  2011-02-24       Impact factor: 17.173

6.  Morphine, D-Pen2, D-Pen5 enkephalin and U50,488H differentially affect the locomotor activity and behaviours induced by quinpirole in guinea-pigs.

Authors:  P J Brent; G Bot
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum.

Authors:  Kelly E Bosse; Emily M Jutkiewicz; Margaret E Gnegy; John R Traynor
Journal:  Neuropharmacology       Date:  2008-06-18       Impact factor: 5.250

8.  Mesoaccumbens dopamine-opiate interactions in the control over behaviour by a conditioned reinforcer.

Authors:  G D Phillips; T W Robbins; B J Everitt
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

9.  Influence of naloxone upon motor activity induced by psychomotor stimulant drugs.

Authors:  D N Jones; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

10.  Morphine induces c-fos and junB in striatum and nucleus accumbens via D1 and N-methyl-D-aspartate receptors.

Authors:  J Liu; J Nickolenko; F R Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.